Please login to the form below

Not currently logged in
Email:
Password:

Aristada

This page shows the latest Aristada news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Praluent. hypercholesterolaemia. PCSK9 inhibitor. Regeneron/Sanofi. USA. aripiprazole lauroxil. Aristada. schizophrenia. atypical antipsychotic (D2 partial agonist).

Latest news

  • Alkermes depression drug misses targets in phase III Alkermes depression drug misses targets in phase III

    Alkermes is in the throes of launching its new long-acting schizophrenia treatment Aristada (aripiprazole lauroxil), which was approved by the FDA in October.

  • FDA approves Alkermes’ long-acting Abilify FDA approves Alkermes’ long-acting Abilify

    Aristada given the nod as injectable antipsychotic. Alkermes' Aristada (aripiprazole lauroxil) has been approved by the FDA as a long-acting injectable version of Abilify. ... The approval of Aristada will come as further bad news to Otsuka as Abilify

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics